Menu
Currency
GWAS Study

Genome-wide association study of REM sleep behavior disorder in Parkinson's disease.

Sosero YL, Heilbron K, Fontanillas P et al.

40998812 PubMed ID
GWAS Study Type
18423 Participants
72 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

SY
Sosero YL
HK
Heilbron K
FP
Fontanillas P
NL
Norcliffe-Kaufmann L
YE
Yu E
RU
Rudakou U
RJ
Ruskey JA
FK
Freeman K
AF
Asayesh F
BK
Brolin KA
SM
Swanberg M
MH
Morris HR
WL
Wu L
RR
Real R
PL
Pihlstrøm L
TM
Tan M
GT
Gasser T
BK
Brockmann K
LH
Liu H
HM
Hu MTM
GD
Grosset DG
LS
Lewis SJG
KJ
Kwok JB
PP
Pastor P
AI
Alvarez I
SM
Skorvanek M
LA
Lackova A
OM
Ostrozovicova M
RM
Rizig M
KL
Krohn L
GZ
Gan-Or Z
Chapter II

Abstract

Summary of the research findings

REM sleep behavior disorder (RBD), is a prodromal synucleinopathy affecting a subset of Parkinson's disease (PD) patients and associated with neuropsychiatric symptoms. This study compared the genetic profiles of 13,020 PD patients with probable RBD (PD + RBD) and 5403 without (PD-RBD) using genome-wide association study (GWAS). RBD was assessed by questionnaires or self-reporting. Potential genetic correlations between neuropsychiatric traits and PD + RBD were assessed using linkage disequilibrium score regression. The top variant in the SNCA locus was associated with PD + RBD (rs10005233-T, OR = 1.21, 95% CI = 1.16-1.27, p = 1.81e-15). PD risk variants in SNCA (rs5019538-G, OR = 0.85, 95% CI = 0.81-0.89, p = 2.46e-10; rs356182-G, OR = 0.89, 95% CI = 0.84-0.95, p = 0.0001) and LRRK2 loci (rs34637584, OR = 0.41, 95% CI = 0.28-0.61, p = 1.04e-5) were associated with reduced PD + RBD risk. A suggestive genetic correlation between attention deficit hyperactivity disorder and PD + RBD was observed but was not statistically significant after correction. These findings highlight genetic distinctions between PD + RBD and PD-RBD, offering insights into PD stratification and potential subtype-specific treatments.

5,403 cases, 13,020 controls

Chapter III

Study Statistics

Key metrics and study information

18423
Total Participants
GWAS
Study Type
No
Replicated
Canada, Sweden, U.S., Norway, U.K., Slovakia, Australia, Germany, Spain
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.